Spinnaker Trust Has $1.93 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Spinnaker Trust cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,661 shares of the company’s stock after selling 70 shares during the quarter. Spinnaker Trust’s holdings in IDEXX Laboratories were worth $1,927,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of IDXX. Creative Planning increased its position in shares of IDEXX Laboratories by 2.6% during the third quarter. Creative Planning now owns 24,436 shares of the company’s stock worth $12,346,000 after buying an additional 614 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of IDEXX Laboratories by 19.0% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 3,306 shares of the company’s stock worth $1,670,000 after buying an additional 529 shares during the period. Bleakley Financial Group LLC increased its position in shares of IDEXX Laboratories by 1.4% during the third quarter. Bleakley Financial Group LLC now owns 2,861 shares of the company’s stock worth $1,445,000 after buying an additional 39 shares during the period. Marshall Financial Group LLC increased its position in shares of IDEXX Laboratories by 1.6% during the third quarter. Marshall Financial Group LLC now owns 1,884 shares of the company’s stock worth $952,000 after buying an additional 30 shares during the period. Finally, Cardinal Capital Management increased its position in shares of IDEXX Laboratories by 0.7% during the third quarter. Cardinal Capital Management now owns 13,919 shares of the company’s stock worth $7,032,000 after buying an additional 93 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 3.3 %

IDEXX Laboratories stock opened at $444.53 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market capitalization of $36.40 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The firm’s fifty day moving average price is $430.77 and its two-hundred day moving average price is $453.31. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 over the last ninety days. Corporate insiders own 2.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, Morgan Stanley cut their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.